Dr. Mark Bontreger

Dr. Mark Bontreger (Watertown, SD) is a SAMHSA Behavioral Health Treatment Services Locator-registered facility. The facility's programming is outpatient (IOP, Dual Dx), not residential. Evaluation of this facility against current clinical standards should encompass ASAM 4e framework alignment, MAT policy, and payer-specific network status.

Care levels at Dr. Mark Bontreger

Level-of-care documentation: Dr. Mark Bontreger is an outpatient-focused program (IOP, Dual Dx) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Under MHPAEA 2024 medical-necessity criteria disclosure, plan-specific criteria for each of these levels must be available to patients upon request. Mismatch between documented clinical need and offered level of care is a common source of authorization denial.

Insurance and payment

Payment and insurance posture: Payment and insurance specifics for Dr. Mark Bontreger are not fully documented in the SAMHSA registry — a direct admissions conversation is the reliable way to confirm what forms of payment are accepted and at what network-contract level. Pre-admission Verification of Benefits (VOB) documentation should include: specific plan product and network status, deductible status at time of admission, coinsurance rate applicable, prior authorization status and turnaround, and out-of-pocket accumulation. Under MHPAEA 2024 disclosure rules, plan-specific medical-necessity criteria must be available on request.

Specialty programming

The facility's documented specialty programming includes: Young adults, Adult women, Pregnant/postpartum women. Specialty-program verification requires review of: (a) dedicated specialty-track programming hours per week; (b) specialty-credentialed clinical staffing (e.g., LCSW with trauma specialization, perinatal-nurse certification, adolescent-development training); (c) specialty-specific clinical assessment protocols; (d) specialty-specific outcome measurement. Marketing designation alone is insufficient for clinical confidence.

Before you call

Pre-admission due-diligence for Dr. Mark Bontreger: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via SD behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether Dr. Mark Bontreger offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.